title: Current readings: management of N2 disease for lung cancer.
abstract: The optimal management of locally advanced, Stage IIIA NSCLC with N2 level nodal metastases remains challenging and controversial. A number of treatment regimens have been shown safe and effective, but existing clinical trial data frequently falls short of providing guidance to match the right approach with the right patient. We review recent literature in this area and its impact.
authors: Division of General Thoracic Surgery, Department of Surgery, Mayo Clinic College of Medicine Rochester, Minnesota. Electronic address: wigle.dennis@mayo.edu.
authors: Dennis A
authors: DA
authors: Wigle
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality* / Q000473:pathology* / Q000532:radiotherapy* / Q000628:therapy*; D004273:DNA, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality* / Q000473:pathology* / Q000532:radiotherapy* / Q000628:therapy*; D008198:Lymph Nodes / Q000473:pathology*; D008297:Male; D008482:Mediastinum / Q000473:pathology*; D020360:Neoadjuvant Therapy / Q000592:standards*; D011013:Pneumonectomy; D010818:Practice Patterns, Physicians' / Q000639:trends*
chemical_list: D004273:DNA, Neoplasm
keywords: N2 NSCLC; chemotherapy; genomics; lung cancer; radiation therapy; surgery; targeted therapy